☆ 4.6 Article

Interferon may be back on track to treat acute myeloid leukemia

ONCOIMMUNOLOGY (2013)

期刊

ONCOIMMUNOLOGY

卷 2, 期 4, 页码 -

出版社

LANDES BIOSCIENCE

DOI: 10.4161/onci.23619

关键词

acute myeloid leukemia; immunotherapy; interferon; pegylation

类别

Oncology Immunology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Our own experience and a thorough literature review suggest that interferon (IFN) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFN for several months, which can be obtained by using pegylated IFN.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Targeting CD33 for acute myeloid leukemia therapy

Jingjing Liu, Jiayin Tong, Haiping Yang

Summary: This study analyzed the level of CD33 expression in newly diagnosed AML patients and its correlation with clinical characteristics. The results showed that high CD33 expression was associated with FLT3 and NPM1 gene mutations and worse overall survival. High CD33 expression was closely related to normal karyotype, high white blood cell count, and a high ratio of primitive cells.

BMC CANCER (2022)

添加到收藏夹

Review Oncology

Acute Myeloid Leukemia: Is It T Time?

Meriem Ben Khoud, Tiziano Ingegnere, Bruno Quesnel, Suman Mitra, Carine Brinster

Summary: Acute myeloid leukemia (AML) is a cancer characterized by impaired differentiation and excessive expansion of blood progenitor cells leading to their accumulation in the bone marrow and circulation. The disease alters the bone marrow microenvironment, inhibits proper hematopoiesis, and causes sustained cytopenia and immunodeficiency. AML influences the immune system, particularly T lymphocytes, and therapeutic strategies aim to improve the anti-leukemic immune response and patient outcomes.

CANCERS (2021)

添加到收藏夹

Review Oncology

Redirecting the Immune Microenvironment in Acute Myeloid Leukemia

Stephanie Sendker, Dirk Reinhardt, Naghmeh Niktoreh

Summary: Despite progress in treating childhood AML, the risk of relapse and refractory disease remains high. Immunotherapy shows promise as an effective tool against AML, but further research and specific engineering is needed to reduce toxicity.

CANCERS (2021)

添加到收藏夹

Review Cell Biology

Immunotherapy targeting mesothelin in acute myeloid leukemia

Qingguang Wang, Rui Gong

Summary: Mesothelin (MSLN) is an emerging target with potential for the treatment of acute myeloid leukemia (AML). Recent studies have shown high expression of MSLN in AML patients and low expression in normal hematopoietic cells. Decreasing MSLN expression may reduce the severity of AML, making it an ideal target for treatment.

JOURNAL OF LEUKOCYTE BIOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches

Natasa Tosic, Irena Marjanovic, Jelena Lazic

Summary: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that accounts for 20% of pediatric leukemia cases. While overall survival rates have improved, AML remains a leading cause of mortality in pediatric cancers. Targeted therapy approaches and advances in genomic techniques have identified novel therapeutic targets and provided potential for significant clinical benefits in pediatric AML.

BIOCHEMICAL PHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Meghali Goswami, Gege Gui, Laura W. Dillon, Katherine E. Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y. Ghannam, Karolyn A. Oetjen, Christin B. Destefano, Dana M. Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L. Marte, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L. Gulley, Katherine R. Calvo, Catherine Lai, Christopher S. Hourigan

Summary: This study aimed to investigate the feasibility and efficacy of the combination of PD-1 blockade and hypomethylating therapy in patients with R-AML. The results showed that this combination therapy achieved disease stability or better response in some patients. Moreover, clonal T cell expansions and immunological changes were observed during treatment, which may be associated with treatment-related adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Immunology

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

Johanna Rausch, Evelyn Ullrich, Michael W. M. Kuehn

Summary: AML is a malignant disease that is difficult to treat, especially in patients who cannot undergo intensive chemotherapy. Immunotherapy has been successful in treating solid tumors and lymphatic neoplasms, but its efficacy in AML has been limited. Epigenetic dysregulation is a driver of leukemogenesis, and combining targeted epigenetic drugs with immunotherapy may improve treatment outcomes. Further research is needed to understand the immune functions affected by these drugs and their potential for clinical use.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Review Oncology

Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia

Matthew R. Lordo, Steven D. Scoville, Akul Goel, Jianhua Yu, Aharon G. Freud, Michael A. Caligiuri, Bethany L. Mundy-Bosse

Summary: AML is an aggressive form of blood cancer with poor survival rates. Patients with AML often have defects in their immune system, particularly in NK cells. Recent studies are shedding light on the role of other ILC family members in AML, enhancing our understanding of AML treatment.

CANCERS (2021)

添加到收藏夹

Review Immunology

One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia

Zhiding Wang, Jinghong Chen, Mengzhen Wang, Linlin Zhang, Li Yu

Summary: Tim-3 serves as an immune checkpoint in AML, playing a critical role in immune responses and elimination of leukemia stem cells. Its dual functionality as a potential target for curing AML sheds new light on AML immunotherapy.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?

Kordelia Barbullushi, Nicolo Rampi, Fabio Serpenti, Mariarita Sciume, Sonia Fabris, Pasquale De Roberto, Nicola Stefano Fracchiolla

Summary: Immunotherapy is revolutionizing the treatment of hematologic diseases. However, in acute myeloid leukemia (AML), the options have been limited to one approved drug, gemtuzumab ozogamicin. This review focuses on the use of vaccines in AML and discusses their biological mechanisms and clinical impact. Various vaccine strategies have been explored, with promising results in terms of toxicity and application in elderly patients. However, the clinical outcomes are still unsatisfactory, and further research is needed to determine the best approach. Vaccines have advantages of being less toxic and more manageable compared to other immunotherapeutic strategies. However, their effectiveness may be limited in active or high-burden disease. Future studies should aim to optimize immunotherapy-based strategies, including the use of vaccines, to achieve long-term disease control in AML.

CANCERS (2022)

添加到收藏夹

Review Oncology

Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia

Mark Gurney, Michael O'Dwyer

Summary: CAR-NK cells, as an alternative cell therapy, offer advantages such as rapid availability and potentially fewer side effects, making them particularly suitable for the treatment of acute myeloid leukemia (AML). Research indicates that this therapy has the potential to be a new option for AML treatment.

CANCERS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Low doses of IFN-γ maintain self-renewal of leukemia stem cells in acute myeloid leukemia

Xiaoling Xie, Wuju Zhang, Xuan Zhou, Binyan Xu, Hao Wang, Yingqi Qiu, Yuxing Hu, Bin Guo, Zhixin Ye, Le Hu, Honghao Zhang, Yuhua Li, Xiaochun Bai

Summary: Low serum IFN-gamma levels are associated with a higher percentage of LSCs and greater relapse incidence in AML patients. High doses of IFN-gamma have an anti-AML effect, while low doses accelerate AML development and support LSC self-renewal. Targeting IFNGR1 in AML cells induces differentiation and delays leukemogenesis.

ONCOGENE (2023)

添加到收藏夹

Article Immunology

Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia

Gongqiang Wu, Shanshan Guo, Qian Luo, Xiaoxia Wang, Wenhai Deng, Guifang Ouyang, Jeffrey J. Pu, Wen Lei, Wenbin Qian

Summary: This study identified anti-CD70 CAR-T cells as a potential new treatment for AML. However, this CAR-T cell therapy did not completely eliminate leukemia in vivo, suggesting the need for further research and development of innovative combinatorial CAR constructs and increased CD70 expression on leukemia cell surface to optimize CAR-T cell responses for AML.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

Fabio Andreozzi, Fulvio Massaro, Sebastian Wittnebel, Chloe Spilleboudt, Philippe Lewalle, Adriano Salaroli

Summary: For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML). Recently, several new drugs have emerged, providing new opportunities and challenges for the treatment of both fit and unfit AML patients. Access to and inclusion in clinical trials of these new drugs should be encouraged to define the future standard of treatment for AML.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Editorial Material Cell & Tissue Engineering

SEPHguarding acute myeloid leukemia

Malini Gupta, Britta Will

Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.

CELL STEM CELL (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

Gils Roex, Diana Campillo-Davo, Donovan Flumens, Philip Anthony Gilbert Shaw, Laurens Krekelbergh, Hans De Reu, Zwi N. Berneman, Eva Lion, Sebastien Anguille

Summary: CAR T-cell therapy is valuable for treating B-cell malignancies, but can lead to antigen-negative tumor cell outgrowth. Using NK cells as an alternative to T cells and employing a multi-target strategy may be a more effective approach.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Modulating the Antioxidant Response for Better Oxidative Stress-Inducing Therapies: How to Take Advantage of Two Sides of the Same Medal?

Priyanka Shaw, Naresh Kumar, Maxime Sahun, Evelien Smits, Annemie Bogaerts, Angela Privat-Maldonado

Summary: Oxidative stress-inducing therapies utilize the antioxidant defense system to treat diseases. Understanding the mechanisms of endogenous antioxidant systems is crucial for enhancing the efficacy of oxidative stress-based treatments.

BIOMEDICINES (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy

Louis Lauwerys, Evelien Smits, Tim Van den Wyngaert, Filipe Elvas

Summary: Cancer immunotherapy utilizes the body's immune system to eliminate tumors, resulting in significant responses for some patients but also potential adverse events. Non-invasive and sensitive molecular imaging techniques are being increasingly used to monitor immune responses and improve treatment efficacy.

BIOMEDICINES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

Sophie Rovers, Annelies Janssens, Jo Raskin, Patrick Pauwels, Jan P. van Meerbeeck, Evelien Smits, Elly Marcq

Summary: This review provides an overview of the current evidence of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM) and discusses the potential of targeting TIGIT as a novel immunotherapy approach.

BIOMEDICINES (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting hedgehog signaling in pancreatic ductal adenocarcinoma

Delphine Quatannens, Yannick Verhoeven, Peter Van Dam, Filip Lardon, Hans Prenen, Geert Roeyen, Marc Peeters, Evelien L. J. Smits, Jonas Van Audenaerde

Summary: PDAC is a leading cause of cancer related death, with urgent need for effective therapies. Aberrant activation of the Hh signaling pathway in PDAC prompts it as a possible target for treatment, despite ongoing debate on its clinical benefits.

PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Review Oncology

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Raquel S. Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M. Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N. Berneman, Benoit Beuselinck, Kalijn F. Bol, Jannie Borst, An Coosemans, Angeliki Datsi, Jitka Faucikova, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rudiger Sorg, Radek Spisek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I. Jolanda M. de Vries, Yanling Xiao, Abhishek D. Garg

Summary: DC-based vaccination for cancer treatment has advanced significantly over recent decades, but still shows suboptimal anti-tumor efficacy in the clinic. Current efforts are focused on improving the immunogenicity and efficacy of DC vaccines in oncology.

ONCOIMMUNOLOGY (2022)

添加到收藏夹

Review Oncology

New Implications of Patients' Sex in Today's Lung Cancer Management

Jo Raskin, Annemiek Snoeckx, Annelies Janssens, Charlotte De Bondt, Reinier Wener, Mick van de Wiel, Jan P. van Meerbeeck, Evelien Smits

Summary: This paper highlights the importance of considering sex as a significant factor in modern thoracic oncology practice. It discusses the differences between males and females in lung cancer demographics, immune system responses, presence of oncogenic drivers, and response to targeted therapies. The paper also emphasizes the need for targeted smoking cessation campaigns for women and the importance of including women in lung cancer screening trials.

CANCERS (2022)

添加到收藏夹

Meeting Abstract Oncology

Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients

Y. Debie, J. Van Audenaerde, T. Vandamme, L. Croes, L-A. M. N. Teuwen, L. Verbruggen, G. Vanhoutte, E. Marcq, D. Le Blon, B. Peeters, M. E. Goossens, K. Arien, S. Anguille, E. Smits, C. Vulsteke, E. Lion, M. Peeters, P. A. van Dam

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer

Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam

Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening

Christophe Deben, Edgar Cardenas de la Hoz, Maxim Le Compte, Paul Van Schil, Jeroen M. H. Hendriks, Patrick Lauwers, Suresh Krishan Yogeswaran, Filip Lardon, Patrick Pauwels, Steven Van Laere, Annemie Bogaerts, Evelien Smits, Steve Vanlanduit, Abraham Lin

Summary: A high-throughput and automated live-cell image analysis software called OrBITS was developed for kinetic monitoring of organoids. The software combines computer vision with convolutional network machine learning and was validated against standard assays. Using OrBITS, the drug screening of lung and pancreatic cancer treatments provided further insights into the drugs' mechanism of action.

CELLULAR ONCOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Acquired non-thermal plasma resistance mediates a shift towards aerobic glycolysis and ferroptotic cell death in melanoma

Abraham Lin, Maxime Sahun, Eline Biscop, Hanne Verswyvel, Jorrit De Waele, Joey De Backer, Claudia Theys, Bart Cuypers, Kris Laukens, Wim Vanden Berghe, Evelien Smits, Annemie Bogaerts

Summary: This study aimed to investigate the mechanisms of NTP therapy sensitivity and resistance by using the first-ever NTP-resistant cell line derived from sensitive melanoma cells. The cells were exposed to NTP for 12 weeks and evaluated against the parental control cells. Transcriptome sequencing and metabolic analysis revealed a preference towards aerobic glycolysis and increased vulnerability to lipid peroxidation and ferroptosis in NTP-resistant cells.

DRUG RESISTANCE UPDATES (2023)

添加到收藏夹

Article Oncology

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer

Tal Flieswasser, Astrid van den Eynde, Laurie Freire Boullosa, Joeran Melis, Christophe Hermans, Celine Merlin, Ho Wa Lau, Jonas Van Audenaerde, Filip Lardon, Evelien Smits, Patrick Pauwels, Julie Jacobs

Summary: In this study, the cytotoxic and immune stimulatory potential of an anti-CD70 therapy in NSCLC was explored. The results showed that anti-CD70 therapy resulted in NK-mediated killing of NSCLC cells and increased production of pro-inflammatory cytokines by NK cells. Combination of chemotherapy and anti-CD70 therapy further enhanced NSCLC cell killing and improved survival in vivo.

ONCOIMMUNOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers

Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Christophe Hermans, Celine Merlin, Ho Wa Lau, Elly Marcq, Marlies Verschuuren, Winnok H. De Vos, Filip Lardon, Evelien L. J. Smits, Christophe Deben

Summary: The study aims to enhance the efficacy of auranofin (AF) as a cancer treatment by combining it with the PARP inhibitor olaparib (referred to as 'aurola'). High concentrations of AF and olaparib synergistically induced cytotoxicity in NSCLC and PDAC cell lines with low levels of mutant p53 protein. The combination strategy of oxidative stress induction with PARP inhibition could be a promising treatment for mutant p53 cancers.

ANTIOXIDANTS (2023)

添加到收藏夹

Meeting Abstract Oncology

Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma

S. Rovers, C. Merlin, S. Fisher, A. Nowak, P. Pauwels, F. Lardon, J. Van Meerbeeck, E. Smits, E. Marcq

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Nanobody targeting CD70 for immunoPET imaging in preclinical tumor models

F. Elvas, J. Dewulf, T. Flieswasser, T. Delahaye, C. Vanghestel, A. Miranda, J. Jacobs, E. Smits, T. Van den Wyngaert

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.